86 related articles for article (PubMed ID: 27392996)
1. [Not Available].
Blasco H; Silly S; Tournamille JF; Gyan E; Sénécal D; André V; Colombat P; Guellec CL
Therapie; 2008; 63(1):19-28. PubMed ID: 27392996
[TBL] [Abstract][Full Text] [Related]
2. [The need for a better definition of therapeutic indications of carboxypeptidase in delayed elimination of methotrexate].
Blasco H; Silly S; Tournamille JF; Gyan E; Sénécal D; André V; Colombat P; Le Guellec C
Therapie; 2008; 63(1):19-28. PubMed ID: 18387272
[TBL] [Abstract][Full Text] [Related]
3. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
4. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
5. Glucarpidase for the treatment of life-threatening methotrexate overdose.
Tuffaha HW; Al Omar S
Drugs Today (Barc); 2012 Nov; 48(11):705-11. PubMed ID: 23170306
[TBL] [Abstract][Full Text] [Related]
6. Glucarpidase following high-dose methotrexate: update on development.
Patterson DM; Lee SM
Expert Opin Biol Ther; 2010 Jan; 10(1):105-11. PubMed ID: 19925307
[TBL] [Abstract][Full Text] [Related]
7. [Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].
Cózar Olmo JA; Martínez Colmenero C; Peláez Pleguezuelos I; Leiva Gea I; López García AB; de la Cruz Moreno J
An Pediatr (Barc); 2009 Sep; 71(3):230-4. PubMed ID: 19617010
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
9. [Renal toxicity of high-dose methotrexate].
Garcia H; Leblond V; Goldwasser F; Bouscary D; Raffoux E; Boissel N; Broutin S; Joly D
Nephrol Ther; 2018 Apr; 14 Suppl 1():S103-S113. PubMed ID: 29606256
[TBL] [Abstract][Full Text] [Related]
10. The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity - a review of pharmacological and clinical data.
Kielbowski K; Rosik J; Bakinowska E; Gromowska E; Ustianowski Ł; Szostak B; Pawlik A
Expert Opin Drug Metab Toxicol; 2023; 19(11):741-750. PubMed ID: 37846862
[TBL] [Abstract][Full Text] [Related]
11. Understanding and managing methotrexate nephrotoxicity.
Widemann BC; Adamson PC
Oncologist; 2006 Jun; 11(6):694-703. PubMed ID: 16794248
[TBL] [Abstract][Full Text] [Related]
12. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy.
Krause AS; Weihrauch MR; Bode U; Fleischhack G; Elter T; Heuer T; Engert A; Diehl V; Josting A
Leuk Lymphoma; 2002 Nov; 43(11):2139-43. PubMed ID: 12533039
[TBL] [Abstract][Full Text] [Related]
13. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
[TBL] [Abstract][Full Text] [Related]
14. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
15. Use of glucarpidase (carboxypeptidase-G2) in pediatric cancer patients: 11-year experience of a tertiary center.
Vila R; Rubio-San-Simón A; Zubiaur P; Navares-Gómez M; Gómez-Hernández P; Arce B; Madero L
EJHaem; 2023 Nov; 4(4):1052-1058. PubMed ID: 38024601
[TBL] [Abstract][Full Text] [Related]
16. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
[TBL] [Abstract][Full Text] [Related]
17. Charcoal Hemoperfusion for Methotrexate Toxicity: A Safe and Effective Life-Rescue Alternative When Glucarpidase Is Not Available.
Rosales A; Madrid A; Muñoz M; Dapena JL; Ariceta G
Front Pediatr; 2021; 9():635152. PubMed ID: 34490152
[No Abstract] [Full Text] [Related]
18. Glucarpidase for Treating Adults with Delayed Methotrexate Elimination Due to Impaired Renal Function: An Economic Simulation Analysis.
Kala J; Nelson R; Drudge C; Zhou A; Ward S; Bourque M
Clinicoecon Outcomes Res; 2023; 15():165-179. PubMed ID: 36919083
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
20. Severe methotrexate toxicity precipitated by intravenous radiographic contrast.
Harned TM; Mascarenhas L
J Pediatr Hematol Oncol; 2007 Jul; 29(7):496-9. PubMed ID: 17609630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
